ES2954151T3 - Compuesto para uso en métodos para el tratamiento de la poliquistosis renal - Google Patents

Compuesto para uso en métodos para el tratamiento de la poliquistosis renal Download PDF

Info

Publication number
ES2954151T3
ES2954151T3 ES16760627T ES16760627T ES2954151T3 ES 2954151 T3 ES2954151 T3 ES 2954151T3 ES 16760627 T ES16760627 T ES 16760627T ES 16760627 T ES16760627 T ES 16760627T ES 2954151 T3 ES2954151 T3 ES 2954151T3
Authority
ES
Spain
Prior art keywords
subject
mir
certain embodiments
kidney
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16760627T
Other languages
English (en)
Spanish (es)
Inventor
John R Androsavich
B Nelson Chau
Vishal Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulus Therapeutics Inc
University of Texas System
University of Texas at Austin
Original Assignee
Regulus Therapeutics Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc, University of Texas System, University of Texas at Austin filed Critical Regulus Therapeutics Inc
Application granted granted Critical
Publication of ES2954151T3 publication Critical patent/ES2954151T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16760627T 2015-08-26 2016-08-25 Compuesto para uso en métodos para el tratamiento de la poliquistosis renal Active ES2954151T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210031P 2015-08-26 2015-08-26
PCT/US2016/048603 WO2017035319A1 (en) 2015-08-26 2016-08-25 Methods for treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
ES2954151T3 true ES2954151T3 (es) 2023-11-20

Family

ID=56855838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16760627T Active ES2954151T3 (es) 2015-08-26 2016-08-25 Compuesto para uso en métodos para el tratamiento de la poliquistosis renal

Country Status (14)

Country Link
US (3) US10633657B2 (enExample)
EP (2) EP3340993B1 (enExample)
JP (1) JP6929269B2 (enExample)
KR (2) KR20250049446A (enExample)
CN (2) CN114404440A (enExample)
AU (1) AU2016312590B2 (enExample)
CA (1) CA2995996A1 (enExample)
DK (1) DK3340993T5 (enExample)
ES (1) ES2954151T3 (enExample)
IL (1) IL257596B (enExample)
MA (1) MA44836A (enExample)
MX (1) MX2018002354A (enExample)
RU (1) RU2742300C2 (enExample)
WO (1) WO2017035319A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017370560C1 (en) * 2016-12-05 2022-08-11 Regulus Therapeutics Inc. Modified oligonucleotides for treatment of polycystic kidney disease
EA201991370A1 (ru) * 2016-12-05 2019-12-30 Регьюлэс Терапьютикс Инк. Методы лечения поликистозной болезни почек
CN112585280A (zh) 2018-08-23 2021-03-30 罗氏创新中心哥本哈根有限公司 微小rna-134生物标志物
WO2024026354A2 (en) * 2022-07-27 2024-02-01 The General Hospital Corporation Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd)
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び/又は治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
AU2005224014B9 (en) 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
WO2007126150A1 (ja) * 2006-04-27 2007-11-08 National University Corporation Nagoya University 癌の新規治療用組成物
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
WO2008131191A2 (en) 2007-04-20 2008-10-30 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US8569381B2 (en) * 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
DK2925866T3 (en) * 2012-11-30 2018-10-29 Univ Aarhus CIRCULAR RNA FOR INHIBITING MICRO-RNA
EP3060217B1 (en) * 2013-10-24 2022-06-08 Mayo Foundation for Medical Education and Research Treatment of polycystic diseases with an hdac6 inhibitor
EP3105327A4 (en) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions and methods of using microrna inhibitors
AU2017370560C1 (en) 2016-12-05 2022-08-11 Regulus Therapeutics Inc. Modified oligonucleotides for treatment of polycystic kidney disease
EA201991370A1 (ru) 2016-12-05 2019-12-30 Регьюлэс Терапьютикс Инк. Методы лечения поликистозной болезни почек

Also Published As

Publication number Publication date
DK3340993T3 (da) 2023-08-21
RU2018108206A3 (enExample) 2020-01-14
EP3340993A1 (en) 2018-07-04
CN114404440A (zh) 2022-04-29
JP6929269B2 (ja) 2021-09-01
AU2016312590B2 (en) 2021-12-02
RU2742300C2 (ru) 2021-02-04
WO2017035319A1 (en) 2017-03-02
CN108135922A (zh) 2018-06-08
MA44836A (fr) 2018-07-04
IL257596B (en) 2022-08-01
EP4268891A3 (en) 2024-01-24
DK3340993T5 (da) 2024-10-07
MX2018002354A (es) 2018-12-10
RU2018108206A (ru) 2019-09-27
US10633657B2 (en) 2020-04-28
AU2016312590A1 (en) 2018-03-15
US20190153442A1 (en) 2019-05-23
HK1256883A1 (en) 2019-10-04
NZ740040A (en) 2024-07-26
KR20250049446A (ko) 2025-04-11
EP3340993B1 (en) 2023-06-14
US20220025372A1 (en) 2022-01-27
WO2017035319A8 (en) 2021-03-11
JP2018528945A (ja) 2018-10-04
IL257596A (en) 2018-04-30
US11168325B2 (en) 2021-11-09
US20200231971A1 (en) 2020-07-23
EP4268891A2 (en) 2023-11-01
KR20180080181A (ko) 2018-07-11
CA2995996A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
ES2954151T3 (es) Compuesto para uso en métodos para el tratamiento de la poliquistosis renal
US20250283082A1 (en) Compositions for Treatment of Polycystic Kidney Disease
KR102780365B1 (ko) 다낭성 신장 질환의 치료 방법
HK40101442A (en) Compound for use in methods for treatment of polycystic kidney disease
HK40069750A (en) Methods for treatment of polycystic kidney disease
HK1256883B (en) Compound for use in methods for treatment of polycystic kidney disease
BR112019011164B1 (pt) Composto, oligonucleotídeo modificado e composição farmacêutica
HK40014087A (en) Methods for treatment of polycystic kidney disease
HK40014087B (en) Methods for treatment of polycystic kidney disease